What changed between these versions
A substantive restructuring and expansion. v2 introduces a new section modifying housing loan fees, unrelated to the bill's original focus. For the TBI grant programs, v2 significantly tightens eligibility criteria, expands reporting and oversight requirements, and adds new provisions for coordination with VA facilities and human subjects protections.
Overview
Extensive changes throughout the bill, including the addition of entirely new sections and significant modifications to existing grant program provisions. · v2 narrows eligibility for grant recipients, strengthens oversight and reporting requirements for the TBI grant programs, clarifies coordination with the VA, and introduces a new, unrelated policy on housing loan fees.
The most significant change in v2 is the addition of Section 5, which modifies certain housing loan fees, a policy area entirely distinct from the bill's original focus on traumatic brain injury (TBI) research. For the TBI grant programs, v2 narrows the eligibility criteria for entities receiving grants under both Section 2 and Section 3, requiring demonstrated capabilities in clinical trials and patient care. It also significantly expands the administrative, reporting, and oversight requirements for grant recipients and the independent third-party organization, while clarifying coordination with Veterans Health Administration facilities. Several definitions were also updated or added.
Major additions
This new paragraph specifies that the TBI Innovation Grant Program shall supplement, not supplant, other Department of Veterans Affairs (VA) clinical care and research relating to mTBI, and facilitate coordination with Veterans Health Administration (VHA) facilities for referrals, continuity of care, and dissemination of findings.
This addition clarifies the program's role within the existing VA framework, ensuring it enhances rather than replaces current efforts and promotes integration with VHA services. It emphasizes practical coordination for veterans' care.
This new rule of construction clarifies that the Secretary is not authorized to require prior approval of, or changes to, any clinical protocol, study design, outcome measures, or follow-up schedule of an eligible entity, except as necessary for human subjects protections and patient safety.
This provision limits the Secretary's direct intervention in the scientific and clinical methodologies of grant recipients, aiming to preserve research independence while maintaining essential safety oversight. It provides a safeguard for the autonomy of research design.
This new paragraph grants the Secretary authority to suspend, modify, or terminate a grant if the recipient fails to comply with reporting requirements or other applicable terms and conditions.
This adds a clear enforcement mechanism for grant compliance, providing the Secretary with tools to ensure accountability and proper use of funds. It strengthens the oversight framework of the grant program.
Similar to Section 2(e)(6), this new paragraph grants the Secretary authority to suspend, modify, or terminate a grant under Section 3 if the recipient fails to comply with applicable terms and conditions.
This provides an enforcement mechanism for the research grant program, ensuring accountability for entities receiving grants under this section. It strengthens the Secretary's ability to manage the program effectively.
These new clauses require the independent organization to submit annual reports to the Secretary describing activities, outcome data, and methodology, and to make all data and findings available to the Secretary consistent with privacy laws.
These additions ensure regular communication and data sharing between the independent organization and the Secretary, facilitating oversight and enabling the Secretary to utilize research findings effectively while maintaining patient privacy.
This new rule of construction, similar to Section 2(e)(5), clarifies that neither the Secretary nor the independent organization can require prior approval of, or changes to, clinical protocols, study design, outcome measures, or follow-up schedules, except for human subjects protections and patient safety.
This limits intervention in the research methodologies of grant recipients under Section 3, aiming to preserve scientific independence while ensuring safety. It provides a safeguard for the autonomy of research design.
This new paragraph authorizes the Secretary to conduct surveys of the independent organization to assess its effectiveness in administering the research grant program.
This provides the Secretary with a mechanism to evaluate the performance of the independent third-party organization, ensuring that the administration of the grant program is effective and accountable.
This new section consolidates and expands the reporting requirements to Congress for both grant programs under Sections 2 and 3. It mandates annual reports including findings, descriptions of agreements, policy recommendations, and findings from surveys of the independent organization.
This addition centralizes and strengthens congressional oversight by requiring comprehensive, regular reports on the progress, findings, and recommendations from both grant programs. It ensures greater transparency and accountability to Congress.
This entirely new section modifies the loan fee table in section 3729(b)(2) of title 38, United States Code, by extending the sunset date for certain housing loan fees from 'June 9, 2034' to 'July 14, 2034'.
This addition extends the period during which certain housing loan fees will be collected, impacting veterans utilizing VA housing loan benefits. This is a policy change completely unrelated to the bill's stated purpose of TBI research.
This new definition specifies that 'nonprofit organization' means an organization described in section 501(c)(3) of the Internal Revenue Code of 1986 and exempt from taxation, and includes hospitals, nonprofit health systems, academic medical centers, or clinics involved in neurorehabilitation care or mTBI research.
This addition provides a clear and expanded definition of 'nonprofit organization' for the purposes of the Act, clarifying which types of entities are eligible to receive grants and ensuring consistency in interpretation.
Deletions
This subsection required the Secretary to ensure the TBI Innovation Grant Program aligns with the Staff Sergeant Fox Suicide Prevention Grant Program to provide cohesive support for veterans with mTBI and associated mental health conditions, and to increase research on integrated mTBI and mental health interventions outside traditional VA pathways.
The deletion removes the explicit mandate for direct coordination and alignment with the Staff Sergeant Fox Suicide Prevention Grant Program and the specific directive to research interventions outside traditional VA pathways. While some coordination is still encouraged elsewhere, the direct, programmatic link and specific research directive are removed, potentially reducing the emphasis on integrated mental health support and non-traditional interventions at a programmatic level for Section 2 grants. However, Section 2(c)(2)(A) and (B) still require measuring effectiveness on mental health outcomes and reducing suicidality, so the *goal* remains, but the *method* of coordination is less prescriptive.
This subsection mandated the Secretary to prescribe regulations to carry out Section 2 not later than 180 days after the date of enactment.
The deletion removes the explicit requirement and deadline for the Secretary to issue regulations for the Section 2 grant program. This could allow for more flexibility in program implementation but removes a specific accountability measure for timely establishment of regulatory guidance. However, the program is still mandated to be carried out, implying some form of administrative guidelines will be necessary.
This subsection required the Secretary to submit annual reports to Congress, starting two years after program commencement, detailing findings from both Section 2 and Section 3 studies, and recommendations for Departmental policy and programmatic improvements for TBI treatment.
This subsection was deleted as a standalone provision, but its content was largely incorporated and expanded into the new, consolidated Section 4 (Reports to Congress). Therefore, the reporting requirement itself is not deleted but rather restructured and enhanced, ensuring continued congressional oversight but under a new, unified framework.
This definition specified that the term 'treatment' means clinical interventions, therapeutic devices, or rehabilitation care provided directly to a veteran with TBI.
The deletion of this definition means that the term 'treatment' is no longer explicitly defined within the Act. This could lead to broader or narrower interpretations of what constitutes 'treatment' throughout the bill, depending on how the term is understood in context or by implementing agencies. However, the bill's focus remains on neurorehabilitation treatments, which are generally understood to fall within the scope of the deleted definition.
Modifications
The explicit definition of 'mTBI' within this section ensures consistent terminology throughout the bill. The change from 'establish' to 'carry out a three-year program' emphasizes the time-limited nature of the program for the Secretary.
Before
v1 directed the Secretary to establish a grant program (TBI Innovation Grant Program) to award grants for the development, implementation, and evaluation of approaches and methodologies for prospective randomized control trials for neurorehabilitation treatments for chronic mild TBI (mTBI) in veterans.
After
v2 directs the Secretary to carry out a three-year program (TBI Innovation Grant Program) to award grants for the same purpose, but explicitly defines 'chronic mild traumatic brain injury' as 'mTBI' within this subsection.
This modification significantly narrows the pool of eligible entities by requiring demonstrated capabilities in clinical trials, research, and/or patient care delivery. It ensures that grant recipients have proven experience, potentially leading to more effective and rigorous research, but also potentially excluding newer or less established organizations. The 'catch-all' category is replaced with a specific 'partnership' option.
Before
v1 listed eligible entities as: (1) a nonprofit organization, (2) an academic institution engaged in research with respect to TBI, (3) a non-Department health care provider with expertise in neurorehabilitative therapies, or (4) an entity the Secretary determines appropriate.
After
v2 modifies the eligible entities to require demonstrated capabilities: (1) a nonprofit organization with demonstrated capability to conduct clinical trials and to deliver or research effective neurorehabilitation treatments, (2) an academic institution that conducts significant research on mTBI and has demonstrated capability to conduct clinical trials, (3) a non-Department health care provider with expertise in neurorehabilitative therapies and demonstrated capability to conduct clinical trials and evaluate mTBI treatments, or (4) a partnership or consortium of two or more entities described in paragraphs (1) through (3).
These changes enhance the rigor and utility of the grant program. Requiring durability measurements provides a more comprehensive understanding of treatment effectiveness. Including VA resource information in outreach improves veterans' access to care. Explicitly mandating coordination with VHA facilities strengthens the integration of grant-funded activities with existing VA services, benefiting veterans through better referrals and continuity of care.
Before
v1 outlined uses of funds including designing treatments, conducting studies to improve mental health outcomes, reduce suicidality, and mitigate long-term mTBI effects, providing clinician training and veteran outreach, and establishing partnerships with VA facilities.
After
v2 adds to the uses of funds: (1) for studies, to 'measure durability of outcomes at approximately six months following completion of treatment' (Section 2(c)(2)(C)); (2) for training and outreach, to include 'information on available Department resources and pathways to access such resources' (Section 2(c)(3)); and (3) for partnerships, to include 'coordination with Veterans Health Administration facilities to facilitate referral of eligible veterans, continuity of care, and dissemination of aggregate findings' (Section 2(c)(4)).
These additions increase the administrative burden on applicants but ensure greater transparency, accountability, and ethical conduct. The coordination plan promotes integration with VA services, the budget detail allows for better financial oversight, and human subjects assurances reinforce ethical research practices, directly benefiting veteran participants.
Before
v1 required applications to include a detailed description of proposed activities, expected outcomes, and plans for evaluating effectiveness.
After
v2 adds several new requirements for applications: (D) how the entity will coordinate with VHA facilities for referral, continuity of care, and dissemination of findings; (E) the budget, including administrative/overhead costs; and (F) assurances of compliance with human subjects protections and patient safety regulations.
This change shifts the priority from general experience in treatment/research to a specific emphasis on the capacity for coordination with the VA. This will favor entities that can seamlessly integrate with existing VA healthcare pathways, potentially enhancing veteran access to new treatments and continuity of care, but possibly de-emphasizing entities with strong research but less VA integration capacity.
Before
v1 (as Section 2(e)) stated the Secretary shall give priority to eligible entities with demonstrated experience in delivering or researching effective treatments for mTBI.
After
v2 (as Section 2(e)(2)) states the Secretary shall give priority to eligible entities that have demonstrated the capacity to coordinate with the Department to facilitate referral and continuity of care for veterans.
These modifications significantly increase the detail and frequency of reporting, providing the Secretary with more comprehensive data on financial management, patient safety, and program integration. This enhances oversight and accountability, allowing for better evaluation of the program's effectiveness and safety for veterans.
Before
v1 required annual reports describing grant use, progress, and measured outcomes.
After
v2 specifies that reports must be submitted 'not less frequently than annually during the grant period and not later than 180 days after the end of the grant period'. It also adds requirements for: (D) a detailed accounting of expenditures, including administrative/overhead costs; (E) a description of any adverse events and serious adverse events (including self-harm or suicide-related events); and (F) a description of actions taken pursuant to the coordination plan.
This modification strengthens the Secretary's oversight role by explicitly including financial monitoring and timely report receipt. This ensures greater accountability in grant management and continuous evaluation of the program's impact on veterans until its conclusion.
Before
v1 required the Secretary to ensure rigorous oversight and annually evaluate the efficacy of funded activities.
After
v2 adds to the oversight requirement 'including by monitoring financial compliance and timely receipt of the reports required under paragraph (2)'. It also specifies that annual evaluations continue 'until the termination date specified in subsection (i)(1)'.
This modification ensures that funds allocated for the TBI Innovation Grant Program from general mental health care budgets are truly additional resources and do not reduce funding for existing VA mental health and TBI programs. This protects current services for veterans while allowing for new initiatives.
Before
v1 stated the Secretary may carry out the program using amounts available for general mental health care programs.
After
v2 adds a condition: 'if the use of such amounts supplements, and does not supplant, amounts otherwise available for Department mental health and traumatic brain injury programs'.
While the total authorized appropriation remains $30,000,000 over three years, the rephrasing clarifies it as an annual allocation. The removal of 'pilot program' suggests a more established, albeit time-limited, program. The removal of 'remain available until expended' means funds would typically expire at the end of the fiscal year if not used, potentially affecting the flexibility of grant management.
Before
v1 authorized $30,000,000 for fiscal years 2026 through 2028 to carry out the 'pilot program', which would remain available until expended.
After
v2 authorizes $10,000,000 for 'each of fiscal years 2026 through 2028' to carry out 'this section'. The term 'pilot program' and the 'remain available until expended' clause are removed.
This modification provides the Secretary with the necessary authority to wind down the program gracefully, allowing for the completion of ongoing activities and fulfillment of financial obligations even after the primary grant-awarding authority expires. This ensures continuity for existing grant recipients and proper program closure.
Before
v1 stated the authority to carry out the grant program terminates at the end of the 3-year period beginning on the date of enactment.
After
v2 adds an exception: 'except that the Secretary may continue to use amounts made available to carry out this section after such date solely for the purpose of administering activities and obligations incurred before such termination date'.
Similar to Section 2(b), this modification significantly narrows the pool of eligible entities for the independent research grant program by requiring demonstrated capabilities in clinical trials and patient care delivery. This ensures that grant recipients have proven experience, potentially leading to more effective and rigorous research, but also potentially excluding newer or less established organizations. The 'catch-all' category is replaced with a specific 'partnership' option.
Before
v1 listed eligible entities as: (1) an academic institution that conducts significant research on TBI, (2) a nonprofit organization with expertise in TBI research/neurorehabilitation and demonstrated capabilities in clinical trials/TBI treatment evaluation/patient care, or (3) an entity or partnership the Secretary determines appropriate.
After
v2 modifies the eligible entities to require demonstrated capabilities: (1) a nonprofit organization that has demonstrated the capability to conduct clinical trials and to evaluate traumatic brain injury treatments through patient care delivery, (2) an academic institution that conducts significant research on traumatic brain injury and has demonstrated the capability to conduct clinical trials relating to neurorehabilitation treatments, or (3) a partnership or consortium of two or more entities described in paragraphs (1) and (2).
These additions increase the administrative burden on applicants but ensure greater transparency, accountability, and ethical conduct for the independent research grants. The coordination plan promotes integration with VA services, the budget detail allows for better financial oversight, and human subjects assurances reinforce ethical research practices, directly benefiting veteran participants.
Before
v1 required applications to include a summary of proposed research/treatment activities, methodology, and expected outcomes.
After
v2 adds several new requirements for applications: (4) how the entity will coordinate with VHA facilities for referral, continuity of care, and dissemination of findings; (5) the budget, including administrative/overhead costs; and (6) assurances of compliance with human subjects protections and patient safety regulations.
This modification removes the specific comparison to the National Center for Posttraumatic Stress Disorder and instead emphasizes the required expertise of the independent organization in randomized controlled trials, neurorehabilitation outcomes, and research integrity. This ensures a highly qualified entity administers the program, potentially leading to more robust and credible research outcomes, while also clarifying its independence from the VA.
Before
v1 required the Secretary to enter an agreement with an independent third-party organization 'comparable to the National Center for Posttraumatic Stress Disorder of the Department of Veterans Affairs' to administer the program and carry out studies.
After
v2 requires the Secretary to 'seek to enter' an agreement with an independent organization 'that is not a component of the Department and that has demonstrated expertise in randomized controlled trials, neurorehabilitation outcomes evaluation, and research integrity' to administer the program and carry out studies.
This modification broadens the scope of outcomes to be assessed to include 'enhanced brain health outcomes' and introduces a critical measure of 'durability of outcomes'. This provides a more comprehensive evaluation of treatment effectiveness, moving beyond immediate effects to long-term benefits, which is highly significant for understanding the true impact on veterans.
Before
v1 required the independent organization to analyze data to assess the effect of methodologies on mental health outcomes and long-term recovery.
After
v2 adds 'enhanced brain health outcomes' and specifies 'including, to the extent outcomes are collected under the applicable clinical protocol, durability of outcomes at approximately six months following completion of treatment' to the assessment criteria.
Changing 'evidence-based' to 'data-driven' emphasizes the use of collected data from the program itself. The addition of VHA dissemination ensures that successful practices identified by the independent organization are actively shared with VA clinicians and facilities, promoting the adoption of effective treatments across the VA system for the benefit of veterans.
Before
v1 required identifying evidence-based best practices and providing recommendations for further research or clinical application.
After
v2 changes 'evidence-based' to 'data-driven' best practices and adds 'including recommendations for dissemination to Veterans Health Administration clinicians and facilities (as appropriate)'.
This modification significantly enhances the comprehensiveness of the independent organization's report by requiring summaries of durability of outcomes, adverse events (including self-harm/suicide-related events), and aggregate expenditures. This provides Congress and the Secretary with critical data for evaluating the safety, long-term effectiveness, and financial management of the grant programs, directly impacting veteran safety and program accountability.
Before
v1 required the independent organization's report to Congress and the Secretary to include findings of studies and recommendations for expansion of successful methodologies and standard of care.
After
v2 adds a requirement for the report to include: (C) 'to the extent available from the reports and study materials of grant recipients, a summary of-- (i) the durability of outcomes at approximately six months following completion of treatment, if collected under the applicable clinical protocol; (ii) adverse events and serious adverse events, including self-harm or suicide-related events, if collected under the applicable clinical protocol or in the ordinary course of care; and (iii) aggregate expenditures of grant funds, including administrative or overhead costs.'
Similar to Section 2(f)(1), this modification ensures that funds allocated for the independent research grant program from the National Center for Posttraumatic Stress Disorder's budget are truly additional resources and do not reduce funding for existing VA programs and services. This protects current services for veterans while allowing for new research initiatives.
Before
v1 stated the Secretary may use amounts available for the operating budget of the National Center for Posttraumatic Stress Disorder to carry out the research grant program.
After
v2 adds a condition: 'if the use of such amounts supplements, and does not supplant, amounts otherwise available for Department programs and services'.
This modification significantly narrows the scope of the bill's focus from general 'TBI' to specifically 'chronic mild traumatic brain injury' (mTBI) with a defined symptom persistence criterion. This clarifies the target population for the grant programs, ensuring resources are directed towards veterans experiencing persistent symptoms of mild TBI, which is a more specific and often challenging condition to treat.
Before
v1 defined 'TBI' as 'traumatic brain injury'.
After
v2 defines 'chronic mild traumatic brain injury' and 'mTBI' as 'a mild traumatic brain injury with symptoms that persist for not fewer than six months after the inciting injury, as determined using validated clinical criteria'. The general definition of 'TBI' is removed.
Scope
Fundamental restructuring — Changes are scattered throughout the bill, affecting eligibility, administrative processes, reporting, and oversight for both grant programs, and introducing an entirely new policy area in a separate section. — v2 represents a meaningful change in policy direction by narrowing the focus of the TBI grant programs to more experienced entities and strengthening oversight, while also introducing a new, unrelated policy on housing loan fees. The emphasis on coordination with VHA facilities also represents a clearer policy direction towards integration. — The changes to definitions (e.g., 'mTBI') affect the interpretation of terms used throughout the bill. The new reporting section consolidates and expands requirements previously scattered. The non-supplanting clauses interact with existing VA funding mechanisms. The new housing loan fee section is a standalone policy change that does not interact with the TBI provisions.
Impact analysis
Eligible entities (nonprofit organizations, academic institutions, non-Department health care providers)
Negative (for those no longer eligible), Procedural (for those who must now demonstrate specific capabilities).
Eligibility criteria are significantly narrowed, requiring demonstrated capabilities in clinical trials, research, and/or patient care delivery. The 'catch-all' category for other entities is replaced with a specific 'partnership' option.
Grant applicants and recipients
Procedural (increased burden), Negative (for those unable to meet new requirements).
New and expanded requirements for grant applications (e.g., coordination plans, detailed budgets, human subjects assurances) and periodic reports (e.g., adverse events, durability outcomes, detailed expenditures) are introduced. Enforcement authority for non-compliance is also added.
Veterans with chronic mild TBI (mTBI)
Positive (more targeted research, better coordination), Mixed (potential shift in integrated mental health emphasis).
The bill's focus is explicitly narrowed to 'chronic mild TBI' with a defined symptom persistence. Grant programs now emphasize measuring durability of outcomes, integrating VA resources into outreach, and coordinating with VHA facilities for referrals and continuity of care. The direct programmatic link to the Staff Sergeant Fox Suicide Prevention Grant Program is removed.
Veterans utilizing VA housing loan benefits
Negative (extended fee collection).
The sunset date for certain housing loan fees is extended by over a month, from June 9, 2034, to July 14, 2034.
The Secretary of Veterans Affairs and Department of Veterans Affairs (VA)
Procedural (increased authority and responsibility).
The Secretary gains new enforcement authority for grants, new oversight tools for the independent organization, and clearer mandates for coordination with VHA facilities. The explicit requirement to issue regulations for Section 2 is removed, but the program is still mandated. The Secretary must also now 'seek to enter' an agreement with a more specifically defined independent organization.